Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001171843-25-000866
Filing Date
2025-02-14
Accepted
2025-02-14 16:46:17
Documents
64
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q edsa20241231_10q.htm   iXBRL 10-Q 752427
2 EXHIBIT 31.1 ex_774545.htm EX-31.1 12294
3 EXHIBIT 31.2 ex_774546.htm EX-31.2 12236
4 EXHIBIT 32.1 ex_774547.htm EX-32.1 5213
5 EXHIBIT 32.2 ex_774548.htm EX-32.2 5155
  Complete submission text file 0001171843-25-000866.txt   4637005

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA edsa-20241231.xsd EX-101.SCH 50529
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE edsa-20241231_def.xml EX-101.DEF 350793
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE edsa-20241231_lab.xml EX-101.LAB 296269
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE edsa-20241231_pre.xml EX-101.PRE 380899
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE edsa-20241231_cal.xml EX-101.CAL 27711
67 EXTRACTED XBRL INSTANCE DOCUMENT edsa20241231_10q_htm.xml XML 636740
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Filer) CIK: 0001540159 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37619 | Film No.: 25630196
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)